A Norwegian biotech giant?

Norwegian financier Erik Must has asked state authorities to participate in founding a biotechnology company that can compete with the global leaders in genetic engineering.

Because of Norway's relatively homogenous genetic makeup and its highly developed health care system, Must said, a Norwegian company would have competitive advantages as it conducted genetic research and developed new medications and diagnostic aids for sale to the international pharmaceutical industry. Must said he envisioned a company half-owned by the state, an arrangement that would ensure sufficient start-up capital as well as strong ethical guidelines.